Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies
31. Mai 2024 07:05 ET
|
Invivyd
Newly outlined pathway provides a practical, expedient, repeatable immunobridging approach to potential emergency use authorization of serial, novel monoclonal antibodies (mAbs) to prevent and treat...
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
31. Mai 2024 07:00 ET
|
Invivyd
Mr. Lee joins Invivyd with a history of high-quality commercial execution at Alexion, Biohaven and AmylyxAppointment intended to accelerate the addition of commercial capabilities associated with...
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
29. Mai 2024 07:00 ET
|
Invivyd
WALTHAM, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced...
Invivyd Elects Two New Independent Members to its Board of Directors
22. Mai 2024 07:00 ET
|
Invivyd
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced...
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
13. Mai 2024 16:01 ET
|
Invivyd
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced...
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
09. Mai 2024 16:01 ET
|
Invivyd
Launched PEMGARDA™ in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents with moderate-to-severe immune compromiseReported interim exploratory COVID-19 clinical...
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
07. Mai 2024 07:30 ET
|
Invivyd
Pathway leverages immunobridging approach via serum virus neutralizing antibody (sVNA) titers enabled by prior successful COVID-19 treatment clinical trial “STAMP” conducted with prototype antibody...
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
02. Mai 2024 17:13 ET
|
Invivyd
WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced...
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
30. April 2024 07:30 ET
|
Invivyd
Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel monoclonal antibodiesCompany now expects...
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
15. April 2024 07:30 ET
|
Invivyd
Invivyd Receives HCPCS Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) covering PEMGARDA